Walleye Capital LLC Sells 111,076 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Walleye Capital LLC cut its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 34.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,656 shares of the company’s stock after selling 111,076 shares during the quarter. Walleye Capital LLC owned 0.13% of Revolution Medicines worth $9,302,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in RVMD. CIBC Asset Management Inc increased its stake in shares of Revolution Medicines by 5.7% in the fourth quarter. CIBC Asset Management Inc now owns 5,037 shares of the company’s stock valued at $220,000 after buying an additional 270 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Revolution Medicines by 11.4% during the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company’s stock valued at $186,000 after acquiring an additional 434 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Revolution Medicines by 8.3% during the fourth quarter. Amalgamated Bank now owns 5,707 shares of the company’s stock worth $250,000 after purchasing an additional 435 shares during the period. Arizona State Retirement System grew its stake in shares of Revolution Medicines by 2.0% in the fourth quarter. Arizona State Retirement System now owns 33,905 shares of the company’s stock worth $1,483,000 after purchasing an additional 650 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in Revolution Medicines in the fourth quarter valued at $34,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares of the company’s stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the sale, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. This represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock valued at $650,406 over the last ninety days. 8.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright lifted their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Stifel Nicolaus reduced their target price on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC restated a “buy” rating and set a $59.00 price target on shares of Revolution Medicines in a report on Tuesday, April 8th. UBS Group boosted their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Wedbush reiterated an “outperform” rating and set a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday, February 27th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $66.67.

Revolution Medicines Price Performance

RVMD stock opened at $36.32 on Wednesday. The company’s 50-day moving average is $38.11 and its 200-day moving average is $44.59. The stock has a market capitalization of $6.75 billion, a PE ratio of -10.12 and a beta of 1.37. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). On average, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.